Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper Sells 977 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 977 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now owns 164,269 shares in the company, valued at $4,928,070. This represents a 0.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Colleen Tupper also recently made the following trade(s):

• On Tuesday, March 11th, Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $30.01, for a total value of $313,454.45.
• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $30.00, for a total value of $58,470.00.

Collegium Pharmaceutical Trading Up 0.5 %

NASDAQ COLL traded up $0.15 on Tuesday, hitting $29.82. The company’s stock had a trading volume of 333,477 shares, compared to its average volume of 415,338. Collegium Pharmaceutical, Inc. has a 52-week low of $27.28 and a 52-week high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company’s 50-day simple moving average is $30.88 and its 200 day simple moving average is $32.87. The firm has a market cap of $938.91 million, a P/E ratio of 12.85 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Friday, January 10th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in Collegium Pharmaceutical by 19.5% in the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock worth $50,876,000 after buying an additional 289,335 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after purchasing an additional 64,958 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Collegium Pharmaceutical by 0.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company’s stock valued at $47,603,000 after purchasing an additional 5,480 shares during the period. Geode Capital Management LLC lifted its stake in shares of Collegium Pharmaceutical by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock valued at $29,974,000 after purchasing an additional 5,464 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock valued at $29,586,000 after purchasing an additional 116,327 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.